Burnell Thomas W. reported tax withholding involving 581,718 shares of INTERPACE BIOSCIENCES, INC. at $1.61 for −$937k on Aug 20, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
CEO, President & Chairman
CEO, President & Chairman
Filed Aug 20, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$936,565.98Shares × reported price
Shares traded
581,718Common Stock
Price per share
$1.61Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,455,927Direct
Trade date
Aug 20, 2026Tax withholding
Filed
Aug 20, 2026, 5:59 PM ET0-day reporting delay
Accession
0001493152-26-039528Code F · Transaction 14327
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 20, 2026Option exercise1,966,763$0.00$0Trade 14326
Aug 20, 2026Grant554,018$0.00$0Trade 14330
Aug 20, 2026Option exercise1,966,763$0.00$0Trade 14329
Aug 20, 2026Grant1,966,763$0.00$0Trade 14328
5 transaction rows in this filing. Joint filers share the same rows.

IDXG price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IDXG · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Aug 27, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award. F2: Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations. F3: Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc. F4: On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award. F5: The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.